Asia Tech Times — Technology, science and culture across Asia

Technology, science and culture across Asia

Health

Onward Therapeutics closes NT$900 million Series B

The clinical-stage oncology company raised about US$28 million in two closings and aims to register on the Taipei Exchange's Emerging Stock Board by the end of 2027.

Onward Therapeutics closes NT$900 million Series B

The round

Onward Therapeutics has closed a NT$900 million Series B financing, approximately US$28 million, the company said. The round was raised in two closings, the second of which took place in October 2026. It is the company's first capital increase in Taiwan since a share exchange completed in October 2025 moved its global headquarters from Switzerland to Taiwan. Before that share exchange, it had raised CHF 75.5 million, approximately US$90 million, in earlier rounds.

Proceeds will fund the company's clinical programs, the manufacturing of clinical supplies and early-stage research and development.

The investors

Existing individual and institutional shareholders, among them CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, continued to support the round. New institutional investors included Beiley Biofund, Everbright Biofund, Test Rite International Co., Ltd., Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture and Top Taiwan Venture Capital. Several individual investors also joined.

The pipeline

The company's portfolio holds two clinical-stage programs, an innovative bispecific antibody and an allogeneic cell therapy, and two early-stage drug discovery programs. OT-A201, a tetravalent bispecific antibody, has completed monotherapy dose escalation in solid tumors and advanced to Phase 1b, where planned studies include indication-specific expansion cohorts and combination regimens; in hematologic malignancies, enrollment in a Phase 1a study is expected to be complete by the end of 2026. Preliminary clinical activity, including tumor responses and disease stabilization, has been observed across different cancer types with a manageable safety profile.

OT-C001, an off-the-shelf allogeneic natural killer cell therapy derived from umbilical cord blood, is being evaluated in combination with rituximab in a Phase 1 trial in France in patients with diffuse large B-cell lymphoma who have relapsed after, or are refractory to, prior CAR-T and T-cell engager therapies. Preliminary results indicate a favorable safety profile and several cases of complete metabolic response, with enrollment and follow-up ongoing. The early-stage pipeline comprises a small-molecule onco-metabolism project, OT-S00X, and an antibody program against tumor-associated antigens, OT-A30X.

The listing plan

Onward Therapeutics said it has signed a listing advisory agreement with a securities firm and begun preparing to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. The company also plans to expand its team and start clinical trials in Taiwan.

Ask about this ChatGPT Claude Perplexity